Summary
Protein AMPylation, the transfer of AMP from ATP to protein targets, has been recognized as a new mechanism of host-cell disruption by some bacterial effectors that typically contain a FIC-domain. Eukaryotic genomes also encode one FIC-domain protein, HYPE, which has remained poorly characterized. Here we describe the structure of human HYPE, solved by X-ray crystallography, representing the first structure of a eukaryotic FIC-domain protein. We demonstrate that HYPE forms stable dimers with structurally and functionally integrated FIC-domains and with TPR-motifs exposed for protein-protein interactions. As HYPE also uniquely possesses a transmembrane helix, dimerization is likely to affect its positioning and function in the membrane vicinity. The low rate of autoAMPylation of the wild-type HYPE could be due to autoinhibition, consistent with the mechanism proposed for a number of putative FIC AMPylators. Our findings also provide a basis to further consider possible alternative cofactors of HYPE and distinct modes of target-recognition.
Graphical Abstract
Highlights
-
•
The first crystal structure of a eukaryotic FIC-domain protein is solved
-
•
Interdomain interactions and dimerization of HYPE result in a rigid structure
-
•
TPR-motifs and the active site of the autoinhibited FIC domain are exposed
-
•
In contrast to bacterial FICs, HYPE does not preferentially AMPylate small GTPases
It is well established that posttranslational modifications (PTM) of proteins provide a key mechanism for control of functional states, protein-protein interactions, localization, and stability. Bunney et al. describe new insights into HYPE, the only human protein implicated in PTM by AMPylation.
Introduction
It is well established that posttranslational modifications (PTM) of proteins provide a key mechanism for control of protein functional states, protein-protein interactions, subcellular localization, and stability (Deribe et al., 2010, Kamath et al., 2011). In addition to the best-understood PTM, phosphorylation of proteins, several other common modifications have been identified including methylation, acetylation, and ubiquitination. Very recently AMPylation of eukaryotic proteins was also documented (Yarbrough and Orth, 2009). AMPylation (or adenylylation) is the transfer of AMP from ATP to a Tyr or Thr/Ser residue in target proteins. Most enzymes known to catalyze AMPylation are bacterial effectors that are secreted into infected cells, where they AMPylate small GTPases (Rho and Rab families), causing disruption to the host cell (Müller et al., 2010, Roy and Mukherjee, 2009, Yarbrough et al., 2009). These bacterial effectors are regarded as potential new targets in drug discovery since AMPylation plays an important role in infection (Lewallen et al., 2014).
The majority of bacterial AMPylators incorporate a so-called filamentation induced by cyclic AMP (FIC) domain responsible for AMP transfer (Broncel et al., 2012, Garcia-Pino et al., 2014). Further analysis of bacterial effectors has shown that the cofactor specificity is not restricted to ATP, with some FIC domains catalyzing GMPylation and UMPylation reactions (Feng et al., 2012). Furthermore, FIC domains can also catalyze other reactions instead of NMPylation, such as phosphorylation and phosphocholine transfer (Campanacci et al., 2013, Castro-Roa et al., 2013, Cruz et al., 2014). Nevertheless, as clearly illustrated for phosphocholine transfer by AnkX (Campanacci et al., 2013), the underlying reactions share a common mechanism and involve the transfer of a part of a pyrophosphate-bond-containing metabolite and the cleavage of this bond.
The first reports of AMPylation focused on the structure and function of bacterial FIC proteins (Campanacci et al., 2013, Engel et al., 2012, Feng et al., 2012, Goepfert et al., 2013, Ham and Orth, 2011, Müller et al., 2010, Roy and Mukherjee, 2009, Worby et al., 2009, Xiao et al., 2010, Yarbrough et al., 2009). These data strongly suggest that such a modification, in particular eukaryotic AMPylation, is a reversible and regulatory PTM. However, the scope and precise physiological relevance beyond bacterial infection is currently largely unknown. Interestingly, in eukaryotic genomes only one FIC-domain containing protein has been identified to date, HYPE or FICD, and it is strongly conserved from C. elegans to humans (Yarbrough and Orth, 2009). Domain organization is also conserved and, in addition to the FIC domain, the protein incorporates one transmembrane helix and tetratricopeptide repeat (TPR) motifs. However, very little is known about properties of HYPE with regard to both structure and its function in any of these organisms. Some initial characterizations of HYPE suggest that its FIC domain can catalyze NMPylation, including AMPylation (Engel et al., 2012, Mattoo et al., 2011, Worby et al., 2009). The only functional insight has been recently obtained from a study on Drosophila, where flies lacking HYPE were viable and fertile, but blind due to compromised visual neurotransmission; the link between catalytic functionality of the FIC domain and the phenotype was also established (Rahman et al., 2012).
Here we describe the first crystal structure of a eukaryotic HYPE encompassing the two TPR-motifs, an α-helical linker, and the FIC domain of the human protein. The structure and further analyses reveal several features of HYPE that are distinct from most previously characterized bacterial effectors and suggest a different cellular function for this FIC-domain protein.
Results
3D Structure of the Multidomain, Human HYPE Protein
Structural studies of HYPE were performed using a construct lacking the first 102 amino-acid residues at the N terminus, incorporating a single transmembrane domain (residues 24–44). The construct included two TPR-motifs (residues 105–135 and 140–170), a linker region (residues 170– 215), and the FIC domain (residues 215–432) (Figure 1A). While the portion at the N terminus shares low sequence similarity among different species, sequences within the boundaries of the construct used for structural studies are strongly conserved throughout its length (51% similarity) (Figure S1 available online). Structures of several variants of this multidomain HYPE construct were solved by X-ray crystallography with a resolution of up to 2.5Å (Table 1).
Table 1.
HYPE Construct/Cofactor |
|||||
---|---|---|---|---|---|
Apo | E234G-APCPP | E234G-ATP | E234G-ADP | WT-ADP | |
Synchrotron | Diamond I24 | Diamond I03 | Soleil | home source | ESRF-ID23-1 |
Strategy | line scan | line scan | standard | standard | standard |
Resolution (Å) | 2.48A (2.61–2.48) | 2.98 (3.06–2.98) | 2.7 (2.84–2.7) | 2.54 (2.65–2.54) | 2.98 (3.25–2.98) |
Rmrg | 0.088 (0.854) | 0.159 (0.496) | 0.084 (0.57) | 0.12 (0.814) | 0.197 (0.41) |
Mn (I/sd) | 6.1 (1.0) | 4.4 (1.7) | 7.1 (1.7) | 6.5 (0.9) | 11.8 (5.3) |
Comp (%) | 97.7 (97.7) | 94.7 (94.7) | 98.1 (92.2) | 98.7 (98.7) | 84.0 (43.5) |
Mult | 3.1 (3.0) | 3.5 (3.1) | 3.0 (3.0) | 3.2 (2.5) | 14.0 (7.2) |
CC_Imean | 0.994 (0.701) | 0.981 (0.843) | 0.991 (0.815) | 0.994 (0.546) | 0.993 (0.718) |
Spg | P21 | P1 | P21 | P21 | P21212 |
Mosaicity | 0.18 | 0.34 | 0.17 | 0.94 | 0.2 |
Cell (°) | 71.19, 76.81, 93.19 | 77.1, 83.75, 130.02 | 71.25, 76.11, 92.2 | 71.04, 76.01, 92.03 | 77.86, 109.08, 131.54 |
(Å) | 90, 108.05, 90 | 89.92, 89.56, 89.43 | 90.0, 107.28, 90.0 | 90.0, 107.56, 90.01 | 90.0, 90.0, 90.0 |
Wilson B (Å2) | 63.521 | 39.31 | 43.068 | 68.8 | 51.9 |
PHASER model | 3CUC | ||||
Refinement | |||||
No. reflections | 33,248 | 65,073 | 27,626 | 32,508 | 20,620 |
Rfac/Rfree | 21.24/24.42 | 0.21/0.25 | 0.20/0.26 | 0.21/24 | 0.2/0.26 |
No. atoms | |||||
Protein | 5,053 | 20,412 | 5,051 | 5,062 | 5,172 |
Ligand | 216 | 1,080 | 324 | 225 | 244 |
Water | 158 | 824 | 198 | 145 | 156 |
B factors (Å2) | |||||
Protein | 81.3 | 61.83 | 70.8 | 64.55 | 32.5 |
Ligand | 101.25 | 72.6 | 69.65 | 21.92 | 38.55 |
Water | 62.985 | 37.3 | 59.11 | 48.87 | 21.56 |
Root-mean-square deviations | |||||
Bond lengths (Å) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Bond angles (°) | 1.16 | 1.08 | 1.05 | 1.2 | 1.16 |
As shown in Figure 1B, almost the entire structure of the HYPE construct is composed of α helices that represent the main secondary structure element of the TPR-motifs and the FIC domain, with the linker between them consisting of a single α helix. A surface representation of the protein (Figure 1B, right) illustrates a compact structure with restricted flexibility owing to intramolecular interactions, where each of the three main structural features (TPR-motifs, linker, and FIC domain) interact with the other two.
TPR-motifs are found in a number of different organisms (from bacteria to humans), and the number of TPR repeats, each consisting of two antiparallel α helices, varies (Allan and Ratajczak, 2011, Blatch and Lässle, 1999, D’Andrea and Regan, 2003, Zeytuni and Zarivach, 2012). The presence of only two TPR-motifs in HYPE is unusual; most TPR proteins contain three or more (up to 16) TPR-motifs implicated in protein-protein interactions. The only other example of two TPR-motifs is from the propyl 4-hydroxylase (P4H) α subunit (Pekkala et al., 2004). The structure of the TPR-motifs present in HYPE superimposes well with the structures from P4H, as well as with the more typical three-TPR domain of protein phosphatase 5 (PP5) (Figure 2A). As in other examples, parallel packing of adjacent TPR-motifs generates a right-handed helical conformation, creating a channel (or groove) that can accommodate a polypeptide from another protein (Figure 2A). In many cases, the TPR domains present an additional “capping/solubility” helix C-terminal to the TPRs. In HYPE, it is likely that the linker α helix could have this role and could be considered as a part of the TPR domain (Figure 2A). The initial TPR repeat in all HYPE structures exhibits a high degree of disorder when compared to the rest of the structure; this is reflected in the high thermal-factors for this region and missing side chains where the density is poor. Electron density is improved for the underlying main chain positions, giving confidence in the overall orientation of the helices (Table 1).
The FIC domain of HYPE shares general features of other FIC domain structures as shown by an overlay with the FIC domain from H. pylori and IbpAFic2 (Figure 2B). As defined by Pfam, the common core of the FIC domain includes four α helices (α1–4) (Finn et al., 2010). Additional helices at the N- and C-termini of the core are present in most FIC protein structures and show considerable variation in location and orientation. Several such additional α helices are present in HYPE, three at the N terminus and two at the C terminus. Within the FIC core, two features are present in most known structures: (1) the catalytic loop and (2) the flap (Garcia-Pino et al., 2014) (Figure 2B). The catalytic loop in HYPE proteins, commonly positioned between the core α helices 3 and 4, shares the general signature motif of FIC domains, HxFx(D/E)(A/G)N(G/K)R, represented in HYPE by the sequence HPF(I/V)DGNGRT(S/A)R. The critical His residue within the catalytic motif corresponds to His 363 in the human HYPE (Figure S1). The second feature, the flap, is either a β-hairpin or a loop preceding helix α2; this structure appears to facilitate positioning of the target residue. In HYPE, a loop region between residues 311–324 corresponds to the flap-like structure. A recent exhaustive bioinformatics analysis coupled with homology modeling of FIC domains revealed another feature, an inhibitory motif outside the FIC core (Engel et al., 2012). The inhibitory helix (αinh) contains a common inhibitory signature, (S/T)xxxE(G/N), conserved in HYPE proteins as (T/S)V(A/G)IEN, with the critical Glu residue corresponding to Glu 234 in the human protein (Figures 2B and S1). However, some FIC domain proteins lack αinh, as illustrated here for IbpA2FIc (Figure 2B); the highly similar Vop S protein also lacks αinh (Engel et al., 2012).
The FIC domain has been predicted to be present in many (about 3,000) proteins encoded by all genomes sequenced to date, varying in length and domain organization (Kinch et al., 2009). The crystal structure of HYPE (Figures 1 and S2A) reveals the interaction surfaces between the FIC domain and the linker α helix, and between the FIC domain and α helix 2 of the second TPR-motif (TPR2 α2). The FIC domain interaction surface with the linker is more extensive (≈684 Å2) and contributes residues mainly from the post B α helix; however, residues from α3 and αpost A linker (flanking the catalytic loop), as well as one residue from αinh, are also involved. The contact area between the FIC domain and TPR2 α2 is smaller (≈215 Å2) and restricted to the αpost A and αpost B helices of the FIC domain. The N-terminal portion of the linker also interacts with the TPR2 motif (with residues within TPR2 α1 and α2 helices). Overall, these intramolecular interactions likely result in restricted flexibility for the molecule, where the catalytic site of the FIC domain and TPR-motifs are accessible to cofactor binding and protein-protein interactions, respectively (Figures 1 and S3).
Dimerization of HYPE
The crystal structure of HYPE revealed asymmetric dimers with an interaction surface formed exclusively of FIC domain contacts (Figure 3A). There are two distinct areas of interactions (Figure 3B). The first encompasses αpre A helix, αpre B helix, and their linker. The second area incudes α1 helix and follow up linker, preceding the flap. The first dimerization region is more extensive (≈450 Å2) and involves a number a hydrogen bonds; the second area is smaller (≈375 Å2) with weaker interactions, likely to allow for some flexibility (Figure 3B, insets).
The TPR-motifs and the linker are not involved in dimerization, and all TPR-motifs are exposed for ligand binding. Interestingly, TPR-motifs from each monomer are positioned at the opposite sides of the dimer surface (Figure 3). This arrangement precludes cooperation of TPR repeats from two monomers and would allow interactions with two protein partners, and thus contribute to formation of larger complexes. TPR recognition could also be related to selection of protein targets for PTM (see Discussion).
A further analysis of the properties of HYPE constructs in solution confirmed that dimerization is not restricted to conditions used for crystallization. Using size exclusion chromatography, we showed that the elution profile of HYPE corresponded to dimers, and as expected from the crystal structure, the deletion of TPR-motifs did not disrupt dimerization (Figure 4A). However, mutations of residues at the dimerization surface identified a single residue replacement, L258D, sufficient to generate a HYPE monomer (Figure 4A).
Further properties of the HYPE dimers and monomers were analyzed by small angle X-ray scattering (SAXS) (Figures 4B and S4). In agreement with the crystal structure, the SAXS generated wild-type model was consistent with it being a dimer in solution. In contrast, the parameters generated for the L258D HYPE variant suggest this exists as a monomer in solution.
As discussed further below, dimerization of HYPE results in two transmembrane domains per dimer of the full length HYPE and is likely to have an impact on the relative orientation toward membrane structures and further restrict flexibility (see Discussion).
FIC Domain and Cofactor Binding
There are two critical elements for the enzyme activity of FIC proteins, these are the catalytic loop and, for some FIC domains, also the inhibitory helix (Figure S5). In HYPE, the conformation of the catalytic loop is the same as in other structurally defined FIC enzymes (Garcia-Pino et al., 2014); a scaffold of two α helices (α3 and α4) together with the side chains of the conserved Phe365 and Asn369 of the catalytic loop contribute to its distinct structure. The Phe365 side chain anchors the catalytic loop to the hydrophobic core of the enzyme, whereas the amide group of the conserved Asn369 holds the loop through a network of hydrogen bonds to the peptide backbone. The GNG submotif forms an “anion hole”. In the structure of wild-type HYPE, the inhibitory glutamate, Glu234, from αinh is positioned in the vicinity of the catalytic loop.
In addition to apo structures of HYPE variants, we have also obtained structures with the ATP cofactor bound to an E234G variant and with ADP bound to either the HYPE E234G variant or to wild-type protein (Figures 5A and 5B). The positions of the adenosine moiety, ribose ring, and phosphates from all three structures and orientations of critical residues are generally consistent with the previous insights from structural studies of complexes of other FIC domains with ATP and ATP-related ligands (Engel et al., 2012, Goepfert et al., 2013, Palanivelu et al., 2011, Xiao et al., 2010). The adenosine moiety of the ATP and ADP locks into a hydrophobic pocket formed between α3, αpost A and the flap loop; the side chain residues forming this pocket are Val360 (α3), Leu403 (αpost A), and Val316 (flap). There is also direct coordination by one residue, Asn407 (Figures 5B and 5C). The GNG anion hole (residues 368–370) accommodates the α-phosphate of the nucleotide, mainly through direct hydrogen bonds to the polypeptide backbone. A Mg2+ ion is visible in the E234G variant of HYPE; it bridges the α- and β-phosphates and is coordinated by the conserved Asp367 side chain. The conserved arginine at the C-terminal side of the FIC catalytic loop, Arg374, forms hydrogen bonds with the ribose ring and is also critical for binding of the γ-phosphate. The position of the inhibitory glutamate (Glu234) in the structure of wild-type HYPE is consistent with its role in competing with the Arg374/γ-phospate interaction (Figure 5A). Interestingly, there is a difference in side chain orientation of Glu234 in apo and ADP bound structures of the wild-type HYPE that shows that this side chain can also affect ADP binding and that is sufficiently flexible to accommodate bound ADP (Figure 5A). The position of clearly visible α- and β-phosphates in all three structures is the same, with the α-phosphate present in an orientation compatible with the AMPylation reaction (Figure 5A). This is consistent with previous findings that the engagement of β- and γ-phosphates of ATP or AMPPNP to wild-type FIC proteins is obstructed by the inhibitory glutamate, resulting in a nonproductive orientation of the α-phosphate, while in all structures obtained for glutamate substitutions or deletions, the position of ATP is the same, with a productive orientation of the α-phosphate (Engel et al., 2012, Goepfert et al., 2013). Correct positioning of the α-phosphate in the wild-type HYPE/ADP complex shows that also in the case of HYPE, the γ-phosphate, and to some extent β-phosphate, could preclude efficient and/or enzymatically correct ATP binding to the wild-type protein.
For the transfer reaction catalyzed by FIC enzymes, the productive binding of the nucleotide is achieved by the correct positioning of the conserved Arg374; this in turn allows insertion of the attacking group of the target, facilitated by the flap structure. The conserved His363 in HYPE is well positioned to compete with the catalytic motif that would result in a favorable interaction with a high-energy pyrophosphate bond of the nucleotide to act as a general base in the catalysis, allowing the transfer of the AMP moiety (Figures 5B and 5C). The structure of HYPE E234G with the nonhydrolysable ATP analog, APCPP, shows a different position of the α-phosphate that would be incompatible with catalysis (Figure S6), suggesting that APCPP is not a physiological ATP mimic in this case.
Based on the limited coordination of adenosine in the hydrophobic pocket, it is likely that other nucleotide phosphates or other cofactors can bind to this site. Measurements of binding of a range of ligands to the E234G variant (172–434) using thermal shift analysis excluded phosphocholine as a possible cofactor (utilized by some FIC-domain proteins such as AnkX) (no shift in Tm, data not shown) and showed similar binding of ATP and guanosine-5'-triphosphate, and a less strong binding of cytidine triphosphate and uridine triphosphate (Figure 6A). Interestingly, binding of ADP was stronger than that of ATP. A possible reason could be that ATP adopts a less favorable conformation within the binding pocket compared to free ATP, a constraint that would not apply to ADP. The measurement of the dissociation constant (KD) of ADP binding to the E234G variant determined by isothermal titration calorimetry (ITC) was 160 nM (Figure 6B). Wild-type HYPE also bound ADP (as the only ligand, Figure 6A), but with a considerably lower affinity and KD of 1.5 μM (Figure 6B), possibly owing to electrostatic repulsion by the side chain of by Glu234. Binding of ATP to wild-type HYPE could not be detected using these methods. These findings are in general agreement with the structural data and with the previously proposed role of the inhibitory Glu in obstructing correct engagement of the γ and β phosphates of ATP.
Enzyme Activity of HYPE Variants and Possible Protein Targets
The structures of the HYPE variants with ATP and ADP, direct binding measurements, and earlier work suggest that HYPE can function in protein AMPylation. However, the basal activity of the wild-type HYPE is probably lower when compared to the E234G variant. It has been previously documented that the proposed intramolecular inhibition in several FIC domains (Engel et al., 2012) can be reversed by replacing the critical inhibitory Glu residue by Gly, using autoAMPylation as a readout (Goepfert et al., 2013). Regardless of the physiological relevance of this replacement, conservation of the reaction mechanism (Garcia-Pino et al., 2014) would allow application of this strategy for the analysis of structure-function relationship. Using a chemo-enzymatic tagging and a Yn-6-ATP in vitro probe (Figure S7) (Heal et al., 2012) (compatible with the AMPylation reaction, see Grammel et al., 2011), we were able to show by fast in-gel fluorescence readout, that HYPE can autoAMPylate (Figure 7A). Furthermore, basal activity of the wild-type HYPE was drastically boosted by the E234G mutation. In contrast, mutations of the catalytic His363 or Mg2+-coordinating Asp367 (in the context of the E234G variant) abolished the enzyme activity (both values were about 4%–6% of control), consistent with the conserved reaction mechanism.
We used this autoAMPylation assay to test the functional implications of interdomain interactions on enzyme activity of the FIC domain. Removal of the TPR-motifs (residues 103–172) maintained a stable protein; however, further deletions from the N terminus up to residue 215, that removed the α helix linker, resulted in a highly unstable protein that was insoluble as a single entity. A comparison of constructs that incorporate (residues 103α434, E234G) and lack TPR-motifs (residues 172α445, E234G) show a clear reduction in autoAMPylation in the absence of TPR-motifs (Figure 7B). We also excluded the possibility that this reduction is due to the removal of sites of autoAMPylation that could be present in TPR-motifs. Using a fusion protein of the HYPE variant that is catalytically inactive (SUMO-tag, H363A), the AMPylation of this protein was also reduced to less than 10% when using an E234G construct lacking TPR-motifs. Furthermore, the replacement of potential AMPylation sites in the TPR-motifs (T168A, S170A, and Y172F) did not have an effect on the overall level of autoAMPylation (values within ± 10% of control). Together with structures of the HYPE constructs, this analysis of enzyme activity shows that the FIC domain interactions with the α helix linker and TPR-motifs are required for protein stability and efficient catalytic activity of the FIC domain.
AutoAMPylation activity of the FIC domain appears also to be affected by replacement of residues involved in dimerization or in the vicinity of the dimerization surface (Figure 7C). The activity of the purified L258D variant, which is a monomer in solution, was greatly reduced. Interestingly, some other mutations close to the dimerization surface, not sufficient to disrupt dimerization, also had an impact on autoAMPylation (Figure 7C, top). This suggests that the reduced enzyme activity of the L258D variant may not simply result from the generation of a monomeric form of HYPE. Additionally, the impact of the L258D mutation on autoAMPylation of the E234G, full-length variant, was observed in a cellular setting (Figure 7C, bottom).
While the measurements of autoAMPylation provide some insights into structure-function relationships, the physiological significance of autoAMPylation remains unclear. Furthermore, a cellular substrate of HYPE has not been defined (Garcia-Pino et al., 2014). In our initial experiments addressing this question, we used a Yn-6-ATP-based assay in vitro to compare proteins in cell extract that become AMPylated by HYPE, and by one of the well-studied FIC domain proteins VopS from Vibrio parahaemolyticus that lacks autoinhibition (Figure 7D). As expected, the main AMPylation targets of VopS are in agreement with molecular sizes corresponding to Rho family GTPases. In contrast, small GTPases did not seem to be targeted by E234G (or wild-type) HYPE and, in addition to strong autoAMPylation, several other proteins appear to be AMPylated by the E234G variant. These findings suggest that HYPE may have a range of interacting proteins and targets in cells, and that further development of cell permeable cofactor analogs allowing for profiling in live cells could provide a suitable route to identifying targets of HYPE presented in its physiologically relevant subcellular localization.
Discussion
Recent findings that protein AMPylation is a novel PTM occurring in eukaryotic cells, highlighted the need to better define its role beyond bacterial infection, where FIC-domain containing enzymes are of bacterial origin (Yarbrough and Orth, 2009). We here describe the structural properties of HYPE; a potential AMPylator encoded by eukaryotic genomes, and further analyze and discuss the functional implications of its distinct features.
Eukaryotic HYPE proteins are membrane proteins that uniquely combine one transmembrane helix, two TPR-motifs, and the FIC domain. The structure of the large portion of this protein, including the TPR-motifs, linker region, and FIC domain, summarized in Figure 8, shows that intramolecular interactions result in a rigid arrangement that is extended further by dimerization. TPR-motifs are positioned so that the active site opening in the FIC domain is exposed. Also, intramolecular interactions leave TPR-motifs free to engage in other protein-protein interactions. There are two TPR-motifs of each monomer that are placed at the opposite side of the dimer surface, precluding formation of a larger platform of TPR repeats.
The overall structure of HYPE shows some distinct properties when compared to other proteins that harbor FIC domains or with proteins where TPR domains are combined with other enzyme activities. It appears that to date, FIC-mediated dimerization has not been observed for bacterial effectors, which are in most cases monomeric in solution (Garcia-Pino et al., 2014). An interaction of the FIC domain with a defined domain structure has been described only in one other protein, AnkX, where a similar repeat domain, ankyrin repeat, interacts with the FIC domain so that surfaces usually involved in interactions with other binding partners are involved in intramolecular interactions (Campanacci et al., 2013); this is clearly not the case for HYPE (Figures 1 and S3). The relative orientation of the FIC domain and TPR-motifs in HYPE is also distinct from those observed in PP5 (Figure S3) or Cyp40, two examples where the structures for the full-length TPR-proteins have been determined (Allan and Ratajczak, 2011). In PP5, the TPR domain engages with the catalytic channel of the phosphatase domain, restricting access to the catalytic site, while in Cyp40 the two domains (TPR domain and peptidyl prolyl isomerase domain) are completely independent (Taylor et al., 2001, Yang et al., 2005). Positions observed in HYPE are intermediate between these two examples; there are clear interaction surfaces, centered on the C-terminal α helix of the TPR domain, leaving both the FIC active site and grooves of TPR-motifs exposed (Figures 1 and S3).
TPR repeats (usually three or more) have been predicted to occur in a large number of proteins (about 5,000), and many have been suggested to act as scaffolds for the assembly of multiprotein complexes, such as protein folding complexes, anaphase promoting complex, or the peroxisomal import receptor complex (Allan and Ratajczak, 2011, Blatch and Lässle, 1999, D’Andrea and Regan, 2003, Zeytuni and Zarivach, 2012). In addition to adaptor proteins (such as Hop), some TPR proteins that contain enzyme domains (including PP5 and Cyp40) have been suggested to be part of larger complexes. Although this remains an interesting possibility for HYPE, information available for its function is limited, and there is no clear evidence that it is incorporated into larger complexes. Another possibility is that the TPR-motifs have a role in the recognition of a protein target. TPR-motifs present in the α subunit of tetrameric (α2β2) propyl P4H are mainly involved in substrate (collagen) recognition and have an essential role in collagen synthesis (Pekkala et al., 2004). Furthermore, among the FIC domain proteins, the target binding sites are not conserved and each recognition site is largely influenced by unique target-recognition elements, additional to the FIC α-helical core. For example, in IbpAFic2, an additional “arm domain” provides a large set of unique contacts with the target. This is also an all α-helical lobe domain that protrudes N-terminally from the FIC domain (Xiao et al., 2010). Interestingly, the relative orientation of the arm domain and the FIC core in IbpAFic2 is such that the active site is exposed, as observed for HYPE (Figure S3).
So far, the best-defined targets for FIC–containing proteins are GTPases: Rho GTPases are AMPylated by VopS and IbpA; Rab1 and Rab35 are phosphocholinated by AnkX; and EF-Tu is phosphorylated by Doc; a different example is provided by AvrAC, that targets two kinases (BIK1 and RIPK) by UMPylation (Garcia-Pino et al., 2014). In all these cases, substrate recognition is very specific, and the effect on target function is inhibitory. However, these are all bacterial effectors and targets, and the function of HYPE could be different. Our initial data show clear differences between VopS recognition of Rho GTPases and distinct, potential substrate targets of HYPE (Figure 7D). Assuming the involvement of TPR-motifs in substrate recognition, it has been documented that these motifs have a range of interaction partners. Among TPR-motifs, only the TPRs from p67phox bind a GTPase, namely Rac. The recognition surface is, however, not placed in the TPR groove, but, instead, the binding occurs almost exclusively to the β hairpin insertion element, unique to p67phox (Lapouge et al., 2000).
Our data describing the cofactor binding, where binding of ATP to wild-type HYPE is obstructed by the conserved glutamic acid residue (Figure 5), raise two possibilities. An explanation is based on a concept that the inhibitory α helix and the critical glutamic acid residue obstructing binding of the γ-phosphate of ATP can be removed in the course of a physiologically relevant activation process. This argument is based on a comprehensive analysis of FIC-domain proteins that has identified the conserved inhibitory motif and its coevolution with the conserved FIC motif and putative AMPylation function (Engel et al., 2012). The cofactor binding pockets of FIC domain proteins DOC and AnkX involved in phosphorylation and phosphocholination, respectively, are clearly different from an ADP or ATP binding site in HYPE, and several other proteins with the canonical FIC motif (Engel et al., 2012, Goepfert et al., 2013, Palanivelu et al., 2011). Cofactors are placed in a different orientation, and elements specific for DOC or AnkX facilitate their binding and/or preclude orientation observed in HYPE (Campanacci et al., 2013, Castro-Roa et al., 2013). It has also been observed that wild-type HYPE has low basal levels of AMPylation that are enhanced rather than created by the E234G replacement (Worby et al., 2009, Mattoo et al., 2011, Engel et al., 2012, Yu et al., 2014). However, one important unresolved question with respect to autoinhibition is related to the mechanism that would overcome this inhibitory constraint, leading to activation. The structure of HYPE shows that αinh is held in place by the rest of the structure, and weakening the interaction of αinh with the FIC active site could require significant conformational changes to move the glutamate away from the active site. Therefore, an explanation that the glutamate discriminating against ATP evolved to preclude ATP binding in favor of another cofactor (Campanacci et al., 2013) provides a plausible alternative. While further analysis of a physiologically relevant new cofactor for HYPE would require other experimental approaches, binding studies shown here (Figure 6) suggest that compounds related to nucleotide bisphosphates could be relevant candidates.
Unlike most other FIC domain proteins, HYPE contains a transmembrane helix and is expected to function in membrane proximity. A recent study on Drosophila has suggested that HYPE is localized at the endoplasmic reticulum rather than the plasma membrane (Rahman et al., 2012); our initial data for localization of human HYPE in transfected cells are consistent with this finding (data not shown). Because of the dimer structure of HYPE, and, consequently, two anchor points with cellular membranes per dimer, it is likely that the positioning with respect to the membrane could be less flexible, with restricted orientation (Figure 8). This, in turn, could influence protein-protein interactions and contribute to a more precise assembly of potential, larger complexes or influence target selection.
New insights obtained by structural and functional characterization of HYPE, together with methodologies that may allow discovery of protein targets in cells, provide important steps toward further elucidation of physiological roles of HYPE and the significance of posttranslational modifications mediated by this unique eukaryotic protein.
Experimental Procedures
Constructs
Full length constructs for mammalian expression were cloned into pcDNA-Dest40 (Life Technologies) in frame with a C-terminal mVENUS fluorescent tag and a HIS-tag. Constructs for bacterial expression were cloned into pOPINS (Oxford Protein Production Facility) with boundaries 103–434, 103–445, and 172–445. Point mutations E234G, H363A, T168A, S170A, Y172F, L258D, N262D, I265D, R295E, E259G, E263G, and D367G were introduced in constructs for bacterial expression or, when specified, also in mammalian expression vector. Combinations of point mutations are indicated for specific constructs.
Expression and Purification
The E. coli strain C41(DE3) (Lucigen) was used for expression of most constructs. Transformed cells were grown in 2×YT media containing 50 μg/ml kanamycin at 37°C until an optical density600 of between 0.5 and 0.8. The temperature was decreased to 20°C and expression was induced through the addition of 0.1 mM isopropyl β-D-1-thiogalactopyranoside for 16 hr. Cell lysis was performed on frozen pellets using 25 mM Tris.Cl, 250 mM NaCl, 40 mM Imidazole, and 5 mM Benzamidine.HCl, pH 8.0 with the addition of 0.1 mg/ml lysozyme and 1% (v/v) Triton X-100 at 4°C. Purification was performed using Ni2+ chelating chromatography, followed by cleavage of the His-SUMO tag through the addition of Ulp1 protease. Subsequently, Q-sepharose ion-exchange chromatography and gel filtration chromatography were performed, the protein concentrated to 20 mg/ml and aliquots snap frozen in liquid N2, and stored at −80°C. Transfection of full-length constructs into Freestyle human embryonic kidney (HEK)293F mammalian cells was performed according to manufacturers instructions (Life Technologies).
Crystallography
Apo, wild-type HYPE, was concentrated to 9 mg/ml prior to crystallization via vapor diffusion with 20% polyethylene glycol 3,350, 200 mM Na K Tartrate, and 100mM Bis-Tris Propane pH 7.5 as mother liquor mixed in a 2:1 ratio, plates were then stored at 16°C for crystal growth. Mutant E234G HYPE was crystallized in the same condition. Mutant crystals of a higher quality were achieved with the addition of 10 mM Yn6ATP analog. Initial diffraction experiments revealed no analog in the active site, however. Following crystallization, all crystals were soaked in a cryoprotectant containing mother liquor with a 50% saturated solution of sucrose. Mutant crystals were also soaked with 10mM ATP or ADP alongside 10mM MgCl2.
Data were collected using synchrotron radiation from Diamond Light Source; using line scans to maximize data collection time for apo and APCPP data sets. The ATP data set was collected at Synchrotron Soleil and the ADP data set using a Rigaku home source.
All data sets were processed using the integration program XDS (Kabsch, 2010) with further processing using the CCP4 program Aimless (Winn et al., 2011). Molecular replacement was carried out using the program PHASER (McCoy et al., 2007, Winn et al., 2011). The search model was created from the FIC domain structure 3CUC from the Protein Data Bank (PDB), from Bacterioedes thetaiotaomicron, paired back to shared atoms using the program CHAINSAW (Stein, 2008, Winn et al., 2011). There were two molecules that were found which were rebuilt using the program COOT (Emsley et al., 2010, Winn et al., 2011). N-terminal TPR-motifs were initially not readily visible. To search for the expected helical domains, real space searching was applied with the program FFEAR (Cowtan, 1998, Winn et al., 2011) using a nine residues polyalanine helix as the search model. This resulted in multiple hits together close to the two FIC domains. Careful rebuilding and extension of this region with subsequent refinement using the BUSTER program (Bricogne et al., 2011) produced the long linker helix followed by the N-terminal TPR-motifs. Finally, water molecules and ligands were built into the structure, and the final structure was validated using the Molprobity server (Chen et al., 2010). LigPlot+ (Laskowski and Swindells, 2011) was used for generation of ligand binding diagrams.
ITC
ITC measurements were performed as described previously (Bunney et al., 2009, Bunney et al., 2012). Heats of interaction were measured on a VP-ITC system (Microcal) with a cell volume of 1.458 ml. HYPE molecules were dialyzed for 16 hr in ITC buffer (25 mM Tris.Cl, 150 mM NaCl, 50 mM MgCl2, and 1 mM TCEP, pH 8.0). HYPE was loaded in the sample cell at 100 μM and titrated with ADP in the syringe (1 mM). The titrations were performed while samples were being stirred at 260 revolutions per minute at 20°C. A total of 25 injections were carried out, with 10 μl injected each time (except the first injection, when 3 μl was injected), and a 4 min interval between each injection to allow the baseline to stabilize. The data were fitted with a single site model to calculate the number of binding sites (n), the binding constant (Ka), the change in enthalpy (ΔHo), and change in entropy (ΔS) using Origin software (Microcal, 2004).
Differential Scanning Fluorimetry
Ligand binding experiments were performed on a Stratagene MX3005P machine (Agilent Technologies) running MxPro qPCR software (Agilent Technologies, 2009). Experiments were carried out in 96-well real-time PCR plates with 20 μl samples (duplicates) containing 2 μM protein, 200 μM ligand (or vehicle), 5 mM MgCl2, and 10 × SYPRO Orange dye in 25 mM Tris.Cl, 150 mM NaCl, and 1 mM TCEP, pH 8.0. Fluorescence of the SYPRO Orange dye was monitored in each well over 25–95°C. Curves were analyzed in MS Excel (Microsoft, 2011).
Additional experimental procedures describing western blotting of full-length HYPE constructs expressed in HEK293F cells, SAXS, and AMPylation assays are included in Supplemental Experimental Procedures.
Author Contributions
M.K., E.W.T., and T.D.B. planned the project. T.D.B. and A.R.C. designed and performed experiments covering protein purification (T.D.B.), biophysical characterization (T.D.B.), and crystallography (A.R.C.) and analyzed the data. M.B. designed and performed experiments for AMPylation and thermal shift assays and analyzed the data. D.E. analyzed data from SAXS measurements. A.R.C., T.D.B., and M.K. prepared the figures. M.K. wrote the manuscript and all authors read, corrected, and approved the final manuscript.
Acknowledgments
We thank Catherine S. Watson for assistance with crystallography and ITC experiments and Alice Clark for help with SAXS measurements. We also acknowledge support from the synchrotrons Diamond, Soleil, and European Synchrotron Radiation Facility (ESRF). The M.K. laboratory is supported by Cancer Research UK and M.B. by German Research Foundation (DFG, grant BR 4387/1-1) and European Union (Marie Curie Intra European Fellowship PIEF-GA-2011-299740).
Published: November 26, 2014
Footnotes
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Supplemental Information includes Supplemental Experimental Procedures and seven figures and can be found with this article online at http://dx.doi.org/10.1016/j.str.2014.10.007.
Contributor Information
Tom D. Bunney, Email: t.bunney@ucl.ac.uk.
Matilda Katan, Email: m.katan@ucl.ac.uk.
Accession Numbers
The crystal structures of HYPE have been deposited in the PDB with the accession codes, 4U04 (apo), 4U07 (E234G variant/ATP bound), 4U0S (E234G variant/ATD bound), 4U0U (wild type/ATD bound), and 4U0Z (E234G variant/APCPP bound).
Supplemental Information
References
- Allan R.K., Ratajczak T. Versatile TPR domains accommodate different modes of target protein recognition and function. Cell Stress Chaperones. 2011;16:353–367. doi: 10.1007/s12192-010-0248-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Blatch G.L., Lässle M. The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. BioEssays. 1999;21:932–939. doi: 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
- Bricogne G., Blanc E., Brandl M., Flensburg C., Keller P., Paciorek W., Roversi P., Sharff A., Smart O.S., Vonrhein C. Global Phasing Ltd.; Cambridge, UK: 2011. BUSTER Version 2.10.0. [Google Scholar]
- Broncel M., Serwa R.A., Tate E.W. A new chemical handle for protein AMPylation at the host-pathogen interface. ChemBioChem. 2012;13:183–185. doi: 10.1002/cbic.201100743. [DOI] [PubMed] [Google Scholar]
- Bunney T.D., Opaleye O., Roe S.M., Vatter P., Baxendale R.W., Walliser C., Everett K.L., Josephs M.B., Christow C., Rodrigues-Lima F., et al. Structural insights into formation of an active signaling complex between Rac and phospholipase C gamma 2. Mol. Cell. 2009;34:223–233. doi: 10.1016/j.molcel.2009.02.023. [DOI] [PubMed] [Google Scholar]
- Bunney T.D., Esposito D., Mas-Droux C., Lamber E., Baxendale R.W., Martins M., Cole A., Svergun D., Driscoll P.C., Katan M. Structural and functional integration of the PLCγ interaction domains critical for regulatory mechanisms and signaling deregulation. Structure. 2012;20:2062–2075. doi: 10.1016/j.str.2012.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Campanacci V., Mukherjee S., Roy C.R., Cherfils J. Structure of the Legionella effector AnkX reveals the mechanism of phosphocholine transfer by the FIC domain. EMBO J. 2013;32:1469–1477. doi: 10.1038/emboj.2013.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Castro-Roa D., Garcia-Pino A., De Gieter S., van Nuland N.A., Loris R., Zenkin N. The Fic protein Doc uses an inverted substrate to phosphorylate and inactivate EF-Tu. Nat. Chem. Biol. 2013;9:811–817. doi: 10.1038/nchembio.1364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen V.B., Arendall W.B., 3rd, Headd J.J., Keedy D.A., Immormino R.M., Kapral G.J., Murray L.W., Richardson J.S., Richardson D.C. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 2010;66:12–21. doi: 10.1107/S0907444909042073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cowtan K. Modified phased translation functions and their application to molecular-fragment location. Acta Crystallogr. D Biol. Crystallogr. 1998;54:750–756. doi: 10.1107/s0907444997016247. [DOI] [PubMed] [Google Scholar]
- Cruz J.W., Rothenbacher F.P., Maehigashi T., Lane W.S., Dunham C.M., Woychik N.A. Doc toxin is a kinase that inactivates elongation factor Tu. J. Biol. Chem. 2014;289:7788–7798. doi: 10.1074/jbc.M113.544429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- D’Andrea L.D., Regan L. TPR proteins: the versatile helix. Trends Biochem. Sci. 2003;28:655–662. doi: 10.1016/j.tibs.2003.10.007. [DOI] [PubMed] [Google Scholar]
- Deribe Y.L., Pawson T., Dikic I. Post-translational modifications in signal integration. Nat. Struct. Mol. Biol. 2010;17:666–672. doi: 10.1038/nsmb.1842. [DOI] [PubMed] [Google Scholar]
- Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010;66:486–501. doi: 10.1107/S0907444910007493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Engel P., Goepfert A., Stanger F.V., Harms A., Schmidt A., Schirmer T., Dehio C. Adenylylation control by intra- or intermolecular active-site obstruction in Fic proteins. Nature. 2012;482:107–110. doi: 10.1038/nature10729. [DOI] [PubMed] [Google Scholar]
- Feng F., Yang F., Rong W., Wu X., Zhang J., Chen S., He C., Zhou J.M. A Xanthomonas uridine 5′-monophosphate transferase inhibits plant immune kinases. Nature. 2012;485:114–118. doi: 10.1038/nature10962. [DOI] [PubMed] [Google Scholar]
- Finn R.D., Mistry J., Tate J., Coggill P., Heger A., Pollington J.E., Gavin O.L., Gunasekaran P., Ceric G., Forslund K., et al. The Pfam protein families database. Nucleic Acids Res. 2010;38:D211–D222. doi: 10.1093/nar/gkp985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Garcia-Pino A., Zenkin N., Loris R. The many faces of Fic: structural and functional aspects of Fic enzymes. Trends Biochem. Sci. 2014;39:121–129. doi: 10.1016/j.tibs.2014.01.001. [DOI] [PubMed] [Google Scholar]
- Goepfert A., Stanger F.V., Dehio C., Schirmer T. Conserved inhibitory mechanism and competent ATP binding mode for adenylyltransferases with Fic fold. PLoS ONE. 2013;8:e64901. doi: 10.1371/journal.pone.0064901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Grammel M., Luong P., Orth K., Hang H.C. A chemical reporter for protein AMPylation. J. Am. Chem. Soc. 2011;133:17103–17105. doi: 10.1021/ja205137d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ham H., Orth K. De-AMPylation unmasked: modulation of host membrane trafficking. Sci. Signal. 2011;4:pe42. doi: 10.1126/scisignal.2002458. [DOI] [PubMed] [Google Scholar]
- Heal W.P., Wright M.H., Thinon E., Tate E.W. Multifunctional protein labeling via enzymatic N-terminal tagging and elaboration by click chemistry. Nat. Protoc. 2012;7:105–117. doi: 10.1038/nprot.2011.425. [DOI] [PubMed] [Google Scholar]
- Kabsch W. Xds. Acta Crystallogr. D Biol. Crystallogr. 2010;66:125–132. doi: 10.1107/S0907444909047337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kamath K.S., Vasavada M.S., Srivastava S. Proteomic databases and tools to decipher post-translational modifications. J. Proteomics. 2011;75:127–144. doi: 10.1016/j.jprot.2011.09.014. [DOI] [PubMed] [Google Scholar]
- Kinch L.N., Yarbrough M.L., Orth K., Grishin N.V. Fido, a novel AMPylation domain common to fic, doc, and AvrB. PLoS ONE. 2009;4:e5818. doi: 10.1371/journal.pone.0005818. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lapouge K., Smith S.J., Walker P.A., Gamblin S.J., Smerdon S.J., Rittinger K. Structure of the TPR domain of p67phox in complex with Rac.GTP. Mol. Cell. 2000;6:899–907. doi: 10.1016/s1097-2765(05)00091-2. [DOI] [PubMed] [Google Scholar]
- Laskowski R.A., Swindells M.B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 2011;51:2778–2786. doi: 10.1021/ci200227u. [DOI] [PubMed] [Google Scholar]
- Lewallen D.M., Sreelatha A., Dharmarajan V., Madoux F., Chase P., Griffin P.R., Orth K., Hodder P., Thompson P.R. Inhibiting AMPylation: a novel screen to identify the first small molecule inhibitors of protein AMPylation. ACS Chem. Biol. 2014;9:433–442. doi: 10.1021/cb4006886. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mattoo S., Durrant E., Chen M.J., Xiao J., Lazar C.S., Manning G., Dixon J.E., Worby C.A. Comparative analysis of Histophilus somni immunoglobulin-binding protein A (IbpA) with other fic domain-containing enzymes reveals differences in substrate and nucleotide specificities. J. Biol. Chem. 2011;286:32834–32842. doi: 10.1074/jbc.M111.227603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Cryst. 2007;40:658–674. doi: 10.1107/S0021889807021206. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Müller M.P., Peters H., Blümer J., Blankenfeldt W., Goody R.S., Itzen A. The Legionella effector protein DrrA AMPylates the membrane traffic regulator Rab1b. Science. 2010;329:946–949. doi: 10.1126/science.1192276. [DOI] [PubMed] [Google Scholar]
- Palanivelu D.V., Goepfert A., Meury M., Guye P., Dehio C., Schirmer T. Fic domain-catalyzed adenylylation: insight provided by the structural analysis of the type IV secretion system effector BepA. Protein Sci. 2011;20:492–499. doi: 10.1002/pro.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pekkala M., Hieta R., Bergmann U., Kivirikko K.I., Wierenga R.K., Myllyharju J. The peptide-substrate-binding domain of collagen prolyl 4-hydroxylases is a tetratricopeptide repeat domain with functional aromatic residues. J. Biol. Chem. 2004;279:52255–52261. doi: 10.1074/jbc.M410007200. [DOI] [PubMed] [Google Scholar]
- Rahman M., Ham H., Liu X., Sugiura Y., Orth K., Krämer H. Visual neurotransmission in Drosophila requires expression of Fic in glial capitate projections. Nat. Neurosci. 2012;15:871–875. doi: 10.1038/nn.3102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roy C.R., Mukherjee S. Bacterial FIC proteins AMP up infection. Sci. Signal. 2009;2:pe14. doi: 10.1126/scisignal.262pe14. [DOI] [PubMed] [Google Scholar]
- Stein N. CHAINSAW: a program for mutating pdb files used as templates in molecular replacement. J. Appl. Cryst. 2008;41:641–643. [Google Scholar]
- Taylor P., Dornan J., Carrello A., Minchin R.F., Ratajczak T., Walkinshaw M.D. Two structures of cyclophilin 40: folding and fidelity in the TPR domains. Structure. 2001;9:431–438. doi: 10.1016/s0969-2126(01)00603-7. [DOI] [PubMed] [Google Scholar]
- Winn M.D., Ballard C.C., Cowtan K.D., Dodson E.J., Emsley P., Evans P.R., Keegan R.M., Krissinel E.B., Leslie A.G., McCoy A., et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 2011;67:235–242. doi: 10.1107/S0907444910045749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Worby C.A., Mattoo S., Kruger R.P., Corbeil L.B., Koller A., Mendez J.C., Zekarias B., Lazar C., Dixon J.E. The fic domain: regulation of cell signaling by adenylylation. Mol. Cell. 2009;34:93–103. doi: 10.1016/j.molcel.2009.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Xiao J., Worby C.A., Mattoo S., Sankaran B., Dixon J.E. Structural basis of Fic-mediated adenylylation. Nat. Struct. Mol. Biol. 2010;17:1004–1010. doi: 10.1038/nsmb.1867. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yang J., Roe S.M., Cliff M.J., Williams M.A., Ladbury J.E., Cohen P.T., Barford D. Molecular basis for TPR domain-mediated regulation of protein phosphatase 5. EMBO J. 2005;24:1–10. doi: 10.1038/sj.emboj.7600496. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yarbrough M.L., Orth K. AMPylation is a new post-translational modiFICation. Nat. Chem. Biol. 2009;5:378–379. doi: 10.1038/nchembio0609-378. [DOI] [PubMed] [Google Scholar]
- Yarbrough M.L., Li Y., Kinch L.N., Grishin N.V., Ball H.L., Orth K. AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and downstream signaling. Science. 2009;323:269–272. doi: 10.1126/science.1166382. [DOI] [PubMed] [Google Scholar]
- Yu X., Woolery A.R., Luong P., Hao Y.H., Grammelc M., Westcottc N., Parka J., Wanga J., Biana X., Demirkana G., Hang H.C., et al. Click chemistry-based detection of global pathogen-host AMPylation on self-assembled human protein microarrays. Mol Cell Proteomics. 2014 doi: 10.1074/mcp.M114.041103. Jul 29. pii: mcp.M114.041103. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zeytuni N., Zarivach R. Structural and functional discussion of the tetra-trico-peptide repeat, a protein interaction module. Structure. 2012;20:397–405. doi: 10.1016/j.str.2012.01.006. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.